American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Target densities in malignant and normal cells determine CAR T cell efficacy and off-target hematotoxicity
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Nataraj, S.; Kogel, F.; Chang, Q.; De Stanchina, E.; Fraser, K.; Park, J. H.; Wang, X.; Rivière, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Overcoming heterogeneity in AML with a novel or-gated HITCAR-1XX platform
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Garcia Angus, A.; Chang, Q.; De Stanchina, E.; Sadelain, M.
    Blood (2022)

    Fulltext@MSK | Save
  • Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Dual IKZF2, and CK1α degrader targets acute myeloid leukemia cells
    Meeting Abstract

    Park, S. M.; Miyamoto, D.; Han, G.; Chan, M.; Curnutt, N.; Tran, N.; Velleca, A.; Kim, J. H.; Schurer, A.; Chang, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: Results from the ECOG-ACRIN E1910 Randomized phase III National Cooperative Clinical Trials Network trial
    Meeting Abstract

    Litzow, M. R.; Sun, Z.; Paietta, E.; Mattison, R. J.; Lazarus, H. M.; Rowe, J. M.; Arber, D. A.; Mullighan, C. G.; Willman, C. L.; Zhang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: Results from phase III BMT CTN 1703
    Meeting Abstract

    Holtan, S. G.; Hamadani, M.; Wu, J.; Al Malki, M. M.; Runaas, L.; Elmariah, H.; Rezvani, A. R.; Gooptu, M.; Larkin, K. T.; Shaffer, B. C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
    Journal Article

    Salles, G.; Schuster, S. J.; Dreyling, M.; Fischer, L.; Kuruvilla, J.; Patten, P. E. M.; von Tresckow, B.; Smith, S. M.; Jiménez-Ubieto, A.; Davis, K. L.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save